SkinBioTherapeutics PLC (LON:SBTX) said its subsidiary AxisBiotix has expanded its food supplement study by 50 participants to 250 following a “high level of demand”.
Chief executive Stuart Ashman said he was “overwhelmed” by the “extraordinary number of applicants” in a very short period of time, the majority of which were psoriasis sufferers.
Enrolment began on January 14 for the self-managed assessment, which will be monitored through a mobile app that involves answering questions evaluating symptom progression.
The company, with the help of partner Winclove Probiotics, has developed a food supplement that is a blend of bacterial strains designed to balance the gut microbiome.
Specifically, it is designed to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis.
“The high demand for places on the study underlines just how prevalent skin conditions such as psoriasis are, and how keen sufferers are to try something new and natural to alleviate their symptoms. If we can, we want to help as many people as possible,” said CEO Ashman in a statement.